Overview

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride
Fluoxetine